arrow_back Back to App

$10 Billion Research Boost for Long COVID Treatments and Affordable Care

This Act allocates $10 billion over ten years to accelerate research into the causes, prevention, and treatment of Long COVID and related chronic conditions. It establishes a dedicated research program at the NIH and mandates the creation of specialized clinics and improved provider training to ensure better diagnosis and coordinated care for citizens. A critical provision requires that drugs developed using these federal funds must be sold at fair and reasonable prices, capped by international standards.
Key points
Massive Research Funding: $1 billion annually for 10 years dedicated to intensive research on Long COVID, including pediatric patients and comparison with similar chronic illnesses.
Drug Price Control: Medications and devices developed with federal funding must be reasonably priced and cannot exceed the lowest price charged in six major developed countries (e.g., Canada, UK).
Improved Healthcare Access: Establishment of specialized clinics and training programs for healthcare providers to enhance the quality of care and diagnosis for Long COVID patients.
Patient Involvement: Patients and caregivers are guaranteed representation on the new Advisory Board to directly influence research priorities and funding decisions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_9907
Sponsor: Rep. Omar, Ilhan [D-MN-5]
Process start date: 2024-10-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Long COVID Research Moonshot Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_9907.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-10-01.

What are the main provisions?

Key points include:

  • Massive Research Funding: $1 billion annually for 10 years dedicated to intensive research on Long COVID, including pediatric patients and comparison with similar chronic illnesses.
  • Drug Price Control: Medications and devices developed with federal funding must be reasonably priced and cannot exceed the lowest price charged in six major developed countries (e.g., Canada, UK).
  • Improved Healthcare Access: Establishment of specialized clinics and training programs for healthcare providers to enhance the quality of care and diagnosis for Long COVID patients.
  • Patient Involvement: Patients and caregivers are guaranteed representation on the new Advisory Board to directly influence research priorities and funding decisions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Omar, Ilhan [D-MN-5].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Public Investments